N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis.

doi:10.1016/s0021-9258(17)37202-2

Paper

N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis.

Published Mar 18, 1994 · F. Platt, G. Neises, R. Dwek

The Journal of biological chemistry

Q1 SJR score

444

Citations

12

Influential Citations

Full textSemantic Scholar

Abstract

Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.

In Vitro Study

Highly Cited

Study Snapshot

N-butyldeoxynojirimycin, a novel inhibitor of glycolipid biosynthesis, offers a potential therapeutic approach for managing glycolipid storage disorders like Gaucher's disease.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis.

Sign up to use Study Snapshot

References

Citations